News | April 14, 2025
Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Reaffirms Lupin’s commitment to sustainable resource management
Dr. Muthu was last associated with Mankind Pharma
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Total investment incurred for setting up the new R&D Rs 250 crore
This project is supported by the Irish Government through IDA Ireland
Subscribe To Our Newsletter & Stay Updated
